• In the Pipeline

    Our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients.

    Our Pipeline at a Glance

    As of August 5, 2020

    50+

    Compounds in Development

    40+

    Disease Areas Being Studied

    Like any other scientific endeavor, clinical testing of novel drug compounds is a complex, time-consuming, resource-intensive process with no guaranteed results. But, as described here, Bristol Myers Squibb is committed to pursuing such clinical development and, in doing so, to bringing new hope to patients.

    In the Pipeline Download Pipeline

    Filter

    The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.?

    Brand Name / Compound
    Research Area / Line of Therapy
    Phase 1 P 1
    Phase 2 P 2
    Phase 3 P 3

    Please click on product name to see the Full U.S. Prescribing Information for OPDIVO?, YERVOY?, POMALYST?, EMPLICITI?, IDHIFA?, ISTODAX?, ORENCIA?, NULOJIX?, ELIQUIS?, REVLIMID?, REBLOZYL?,?including Boxed WARNINGS for ELIQUIS?, REVLIMID?, POMALYST?? and Boxed WARNING for YERVOY? regarding immune-mediated adverse reactions and IDHIFA? regarding differentiation syndrome?and INREBIC? regarding encephalopathy including Wernicke's.

    ? Development Partnership: OPDIVO, YERVOY, Relatlimab: Ono (our collaboration with Ono also includes other early stage compounds); EMPLICITI: AbbVie; bempegaldesleukin: Nektar;?Cabozantinib: Exelixis; ELIQUIS: Pfizer; Factor XIa Inhibitor: Janssen; HSP47: Nitto Denko;?CD3xPSCA, GEM333: GeMoaB Monoclonals GmbH; bb21217, ide-cel: bluebird bio; REBLOZYL: Acceleron Pharma, IDHIFA: Agios Pharmaceuticals, Inc.; AHR: Ikena Oncology;?CD22 ADC: TriPhase Accelerator;?TYK2 Inhibitor (Nimbus): Nimbus Therapeutics; Immune Tolerance: Anokion

    ^ Trial(s) exploring various combinations
    # Partner-run study
    ? Product is marketed as IMNOVID? in the EU
    + Idecabtagene vicleucel
    ○ Orvacabtagene autoleucel, being developed by Juno Therapeutics Inc.,?A Bristol-Myers Squibb Company
    * Lisocabtagene maraleucel
    NSCLC = Non-Small Cell Lung Cancer
    SCLC = Small Cell Lung Cancer
    SCCHN = Squamous Cell Carcinoma of the Head & Neck
    HMA = Hypomethylating Agent
    TCE = T-Cell Engager
    ADC = Antibody Drug Conjugate
    ESA = Erythoropoiesis-Stimulating Agent


    For information on approved uses, refer to approved product labeling.Phase I - clinical trials investigating safety of an investigational medicine in a small number of human subjects.Phase II - clinical trials investigating dosing, safety and efficacy of an investigational medicine in a small number of patients who have the disease or condition under study.Phase III - clinical trials investigating the safety and efficacy of an investigational medicine in a larger number of patients who have the disease or condition under study. For purposes of this chart, this includes the regulatory approval process prior to receiving marketing approval in the first major market.
    国产91最新欧美在线观看